drug · small molecule
vebreltinib DR
Phase 2updated 3mo agoby $APLM Apollomics Inc.🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 3 investigational indications.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying vebreltinib DR
- phase3A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
- phase2Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
- phase3Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
- phase2Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- phase2Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that